Bausch + Lomb Co. (NYSE:BLCO) Shares Sold by Maple Rock Capital Partners Inc.

Maple Rock Capital Partners Inc. trimmed its position in Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 3.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,617,548 shares of the company's stock after selling 127,514 shares during the period. Bausch + Lomb comprises about 2.0% of Maple Rock Capital Partners Inc.'s investment portfolio, making the stock its 10th largest position. Maple Rock Capital Partners Inc. owned about 1.03% of Bausch + Lomb worth $69,783,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. River Road Asset Management LLC lifted its holdings in Bausch + Lomb by 4.4% in the 3rd quarter. River Road Asset Management LLC now owns 2,020,414 shares of the company's stock valued at $38,974,000 after purchasing an additional 85,987 shares in the last quarter. Whitebox Advisors LLC lifted its holdings in shares of Bausch + Lomb by 28.2% during the 2nd quarter. Whitebox Advisors LLC now owns 1,545,946 shares of the company's stock worth $22,447,000 after acquiring an additional 339,643 shares during the period. Clearline Capital LP lifted its holdings in shares of Bausch + Lomb by 136.8% during the 2nd quarter. Clearline Capital LP now owns 712,055 shares of the company's stock worth $10,339,000 after acquiring an additional 411,404 shares during the period. Point72 Europe London LLP lifted its holdings in shares of Bausch + Lomb by 28.9% during the 2nd quarter. Point72 Europe London LLP now owns 653,492 shares of the company's stock worth $9,489,000 after acquiring an additional 146,583 shares during the period. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Bausch + Lomb by 31.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 647,156 shares of the company's stock worth $9,397,000 after acquiring an additional 153,000 shares during the period. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on BLCO shares. Royal Bank of Canada increased their price objective on shares of Bausch + Lomb from $20.00 to $23.00 and gave the stock an "outperform" rating in a report on Tuesday, October 22nd. HC Wainwright increased their price objective on shares of Bausch + Lomb from $22.00 to $23.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Needham & Company LLC reissued a "hold" rating on shares of Bausch + Lomb in a research report on Thursday, October 31st. Stifel Nicolaus increased their target price on shares of Bausch + Lomb from $16.00 to $19.00 and gave the stock a "hold" rating in a research report on Monday, September 23rd. Finally, Citigroup increased their target price on shares of Bausch + Lomb from $20.00 to $24.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $21.00.

Bausch + Lomb Stock Up 0.4 %

Shares of BLCO stock traded up $0.07 during mid-day trading on Wednesday, reaching $19.74. 171,999 shares of the company were exchanged, compared to its average volume of 550,464. Bausch + Lomb Co. has a fifty-two week low of $13.16 and a fifty-two week high of $21.69. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.57. The company has a market capitalization of $6.95 billion, a P/E ratio of -18.76, a P/E/G ratio of 1.87 and a beta of 0.43. The business's 50 day simple moving average is $19.80 and its 200 day simple moving average is $17.27.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.01. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the company earned $0.22 earnings per share. The business's quarterly revenue was up 18.8% compared to the same quarter last year. Research analysts predict that Bausch + Lomb Co. will post 0.6 earnings per share for the current year.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.